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SIGNAL transduction plays a vital role in cellular behaviour
as cells respond to various stimuli in different ways and
utilize diverse pathways for accomplishing their task.
Determination of the pathway followed by various cyto-
kines can be achieved using specific inhibitors which
include theophylline (TPH), TMB-8 and W7 that hinder
calmodulin binding to Ca2+; sphingosine (SPH), H7 and
staurosporine that inhibit protein kinase C (PKC)
activation; and mevalonate (MEV) or the anti-p21
antibody which block G-proteins. This study shows that
the immunologically important class II antigens in human
cells are up-regulated predominately via the same pathway
after gamma-interferon (y-IFN) treatment, whereas mur-
ine cells are activated by other signalling routes. Thus, the
calcium/calmodulin (Ca2+/Cam) pathway is preferenti-
ally selected for human cells whereas the PKC pathway is
more often chosen for murine cells. These findings are
firmly supported by other reports and show, in addition,
a unique action exerted by y-IFN, since IL-4, another
inducer of class II antigen expression, uses different
pathways. This diversity of activation reveals the existence
of a previously unknown complicated network of
intracellular interactions able to regulate the same
phenotype or cellular event. As major histocompat-
ibility complex antigens (MHC) or human leukocyte
antigens (HLA), are important in immune recognition and
response, the results show that for human cells a more
coherent method of HLA-DR antigen induction is
followed after y-IFN administration, as calcium participa-
tion seems to be the first step in signal transduction. The
same T-cell derived lymphokine, however, follows a
totally different route when applied to murine cells.
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Introduction
Signal transduction is the term used for the series
of stimuli occurring almost immediately after
administration of a factor that will eventually lead
cells to a mature and/or functional state. The level
of activation may vary according to the transducer
employed. Some agents affect cellular function by
simply binding to specific surface receptors, with
subsequent molecular activation of certain proteins;
whereas other agents trigger a cascade of
intracellular interactions that activate genes and
their products in order to promote a distinct
phenotype or to acquire a specific function not
previously present. Thus, cell cycle kinetics, or
cellular, intracellular and nuclear behaviour can be
manipulated by appropriate treatment(s).
Class II antigens can be activated by many
naturally occurring substances--one of the best
known being y-IFN.
1-5 Previous studies have
shown that y-IFN exerts its action via different
pathways depending on the cellular system
examined and the type of gene under investi-
gation.
5-8 Since immune recognition and response
depend directly on class II antigens,
9 the authors
examined how this agent up-regulates major
histocompatibility complex (MHC)-Ia or human
leukocyte antigen (HLA)-DR antigen expression in
various cell systems. These groups of genes were
chosen as they have been widely studied in murine
and human cells respectively. The three most
common pathways were examined, that is the
2+ 68 310 Ca /Cam’ the PKC’ and the G-protein
system.
11-13
When the Cai+/Cam second messenger pathway
leads to up-regulation of class II surface antigens
on various cells and/or cell lines,6’8 this signalling
mode may be interrupted by administering certain
drugs, such as theophylline (TPH), W7 and
TMB-8 that are known to be potent Cam
68 inhibitors.’ TPH also affects cAMP regulation,
thus making cAMP an additional second messen-
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ger. However, such action appears to be Ca2+/Cam
dependent.
6
PKC, when activated, leads to up-regulation of
class II antigens via indirect means (other gene
activation) as it is generally insufficient by itself to
modulate HLA-DR expression.3’7’1 Documented
inhibitors of this pathway are sphingosine (SPH),
H7 and staurosporine. 3’5’v
The G-protein system participates as a signal
transducer in a multiplicity of ways. One of them
involves the product of the ras proto-oncogene,
p21ras.2’13 It has been shown that induction of p21ras
by y-IFN or 5-azacytidine (5-AzaC) correlates with
class II antigen expression in murine trophoblasts
2
and in HL-60 cells.
13 Inhibitors of such action are
the anti-p21 antibody
13 and mevalonate (MEV;
which is contrary to results found in Ref. 11).
Although each of the above inhibitors acts on,
and is specific for, a different part of its pathway, it
is becoming clear that there is possible ’cross-
talking’ between the pathways, an issue currently
being explored in many laboratories.
14 Each
pathway is, in itself, a complex and often difficult
to follow network of interactions involving
numerous byproducts. Therefore, this work is
based on the assumption that the inhibitors used
are specific for their corresponding pathways and
hence class II antigen expression is indeed the final
product of the various reactions. As this type of
investigation is tedious, the pathway(s) difficult to
follow and the results mixed, well characterized and
well documented inhibitors (see Methods and
Results) were used.
This study shows that y-IFN exhibits a more
stable behaviour in inducing HLA-DR antigens on
human HeLa and HL-60 cells, as Ca2+/Cam appears
to be the major pathway followed. There is
evidence that this agent also follows the same
pathway for human U937 cells
6 and normal
monocytes. In the murine system, however, the
situation is totally different as y-IFN follows either
the Cai+/Cam or the PKC pathway for inducing
MHC-Ia.
An important aspect in the investigation of signal
transduction is the multiplicity of ways a factor may
cause the activation of certain genes. Different
transducers may influence the expression of the
same genes by following totally different and
independent pathways. For instance, it has been
shown that interleukin-4 (IL-4), which also
up-regulates MHC and HLA antigens,
is either
shares or selects distinct pathways for class II
antigen expression. Thus, IL-4 induces HLA-DR
expression via the G-protein system on HL-60 and
normal monocytic cells
13 whereas this present work
shows that it mimics /-IFN when inducing MHC-Ia
antigens on the WEHI-3 murine macrophage-like
cells.
Materials and Methods
Cells and cell cultures: The human epithelial-like cell
line HeLa and the promyelocytic leukaemia HL-60
were purchased from ATCC (Rockville, MD,
USA). The murine macrophage-like cell line
WEHI-3 and the murine pre-B line 70Z were also
purchased from ATCC. For control purposes the
human pre-B cell line 6.1.6 (ATCC) was also used.
HL-60, 70Z and 6.1.6 cells were grown in RPMI
(Gibco, NY, USA) supplemented with 10% FCS
(Seralab, Sussex, UK) and maintained in a
humidified atmosphere of 5% CO2 at 37C. The
growth of HeLa and WEHI-3 cell lines was
supported in Dulbecco’s modified Eagle’s medium
(DMEM, Gibco) using the same conditions as
described above.
Normal human monocytes were purified > 95%)
from human blood by Percoll’s density gradient
centrifugation and adhesion to plastic dishes. Cells
were cultured in RPMI 1640 medium supplemented
with 10% FCS at 37C in 5% CO2.
Inducers of class H antigens and induction protocols: Class II
surface antigens in both murine and human cells
were up-regulated by recombinant 2-IFN (Holland
Biotech, Leiden, Holland, and Genzyme, Boston,
USA for mouse and human IFN respectively) and
recombinant human and murine IL-4 (Genzyme).
Human cells were treated with human factor
preparations, whereas murine cell lines were
cultured with their corresponding species-specific
interleukins.
Doses of y-IFN and IL-4, for the up-regulation
of class II antigens, were selected as described
previously.
8,s Briefly, dose-response curves were
plotted as a function of time and concentrations
were chosen at levels before reaching plateau values
(data not shown). Thus, all cells were treated for
48 h, unless indicated otherwise, with 100 U/ml of
rg-IFN, a dose given at the beginning of the culture.
IL-4 was administered at a concentration of
200 U/ml for HL-60 and 100 U/ml for HeLa and
WEHI-3 cells. As reported previously, a single dose
of IL-4 does not suffice for class 1I induction as it
is rapidly used by the cells, is Therefore, an initial
dose was given at the beginning of the culture and
a second boost 24 h before collecting the cells.
Chemicals/signal transduction inhibitors Theophylline
(TPH), sphingosine (SPH) and mevalovate (MEV)
were all purchased from Sigma chemicals (St Louis,
MO, USA). TPH is known to block the Cae+/Cam
pathway at a concentration of 0.15 mg/ml.
8
Sphingosine, a PKC inhibitor, was used at a final
concentration of 50 nM, whereas MEV, known to
block G-protein activation (laboratory results), was
added at a concentration of 0.5 mg/ml. W7 (Sigma)
a Cam inhibitor (15/IM), staurosporine (UBI, Lake
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Placid, NY) a PKC inhibitor (50 nM) and anti-p21
antibody (Oncogene Sci., Manhasset, NY) a
G-protein inhibitor (1/.tg/ml) were also used and
gave identical results as their reported counterparts
theophylline, sphingosine and mevalonate. Where
not referenced, doses were selected after appropri-
ate toxicity tests (cell viability over 90% as assessed
by Trypan dye exclusion and ability to incorporate
3H-TdR in proliferation assays). All inhibitors were
diluted as instructed in the Merck manual as they
are not water soluble. The tyrosine kinase (TK)
inhibitor genistein (UBI) at 30 tg/ml was used as
an additional control and potential inhibitor of class
II antigens. (See Discussion and legend to
Table 1).
Class II antigen assessment--Dynabead binding and Northern
analysis: MHC Ia and HLA-DR antigens were
determined by specific binding of DynaBeads
(Dynal, Norway) and Northern analysis. For visual
detection murine WEHI-3 cells were first reacted
with an anti-IAd monoclonal antibody (Becton
Dickinson) as these cell derived from a BALB/c
mouse according to standard procedures.
2 70Z cells,
a (b x d) hybrid, were also reacted with the same
IA
d antibody. Then beads coated with an
anti-mouse IgG were added according to the
manufacturer’s instructions. Human cells (HeLa
and HL-60) were incubated directly at 4C with
beads coated with anti-DR antigens as published
previously.
13 Specific binding (rosetting) was
monitored using an Olympus microscope.
Northern analysis was carried out as described
previously.
14 The probes employed were the
PDRH2 fragment (DR 0)s for the human cells and
E0 for the murine counterparts as reported
previously.
2
Results
Results obtained from Dynabead binding experi-
ments, showing the percentage of class I1 antigen
expression in human and murine cells after
treatment with the various agents, are shown in
Table 1. All the inhibitors were used at
non-toxic concentrations (see Methods) as assessed
by cell viability tests (over 90%) and incorporation
of H-TdR (data not shown). Treatment of all cells
with either TPH, SPH or MEV only, did not affect
class I1 antigen expression.
The tyrosine kinase (TK) inhibitor, genistein,
was used as an additional and also potential
inhibitor of class II antigen expression. However,
it was unable to block the antigen expression (data
not shown).
In human pre-B 6.1.6 cells neither 2-IFN nor IL-4
were able to induce class 1I antigen expression (data
not shown). However, high doses of human IL-6
Table 1. Pathways followed during the induction of class II
antigens in human and mouse cells after treatment with
recombinant /-I FN and L-4
Treatment Percentage of class II antigen expression*
Human cells Murine cells
HeLa HL-60 WEHI-3 70Z
None 8 _+ 2 8 _+ 2 8 ___
2 18 _+
TPH 4_+1 7_+2 10_+1 21 _+3
SPH 5 _+ 8 _+ 10 _+ 2 20_+ 5
MEV 6_+ 10_+ 2 11 _+ 20_+
-IFN only 25 _+ 3 45 _+ 2 52 _+ 5 20 _+ 2
-IFN + TPH 8 _+ 2** 16 _+ 3** 48 _+ 4 19 _+ 2
-IFN + SPH 20 _+ 2 40 _+ 5 20 _+ 2** 22 + 3
-IFN + MEV 21 _+ 3 40 _+ 4 48 _+ 4 22 -+ 2
L-4 only 11 _+ 35 -+ 2 40 _+ 2 45 _+ 3
L-4 + TPH 10 _+ 33 _+ 3 35 _+ 3 53 _+ 7
IL-4 + SPH 12 _+ 2 33 _+ 2 7 _+ 2** 26 _+ 2**
L-4 + M EV 10 _+ 2 12 _+ 2** 38 _+ 3 40 _+ 6
As assessed by specific Dynabead binding as described in the
Methods. The experiments have been performed at least four
times and the numbers represent mean values _+ S.D. According
to Student’s t-test, all values marked with an asterisk are
statistically significant compared with their corresponding
induced percentages.
Indicates suppressive agent and pathway of choice when
compared with appropriate controls.
or the combination of LPS + DMSO can be used
successfully as inducers of HLA-DR (data not
shown).
In the human cell lines, HeLa and HL-60,
treatment with y-IFN alone, caused 3- and 6-fold
increases, respectively, in class II antigen expres-
sion. In control experiments y-IFN was unable to
induce these antigens on human pre-B 6.1.6 cells
(data not shown). When SPH or MEV were
included with y-IFN in the assay mixture, antigen
expression was increased by a similar amount to that
with y-IFN alone. However, the inclusion of TPH
with y-IFN caused a significant inhibition of class
I1 antigen expression, and results were similar to
those of untreated cells. Figure 1 shows the results
of Northern blot analysis for the reaction of IFN
and TPH with HeLa cells. The reduced quantity of
antigen expression after reaction with IFN + TPH,
compared with IFN alone, can be seen.
In contrast to y-IFN, in human cells, IL-4 caused
a four-fold increase of class II antigen expression
only in HL-60 cells. This increase was abolished by
the inclusion of MEV in the assay mixture (Table
1).
In the murine cell line WEHI-3, IFN and IL-4
caused seven- and five-fold increases, respectively,
in class I1 antigen expression (Table 1). However,
only IL-4 increased antigen expression in 70Z cells.
In both cell lines, the combination of either
IFN + SPH or IL-4 + SPH significantly reduced
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FIG 1. Northern analysis of human HeLa cells showing that class II
antigen induction at the mRNA level takes place via the Ca2//Cam
pathway after treatment with /-IFN for 48 h. Theophylline (TPH) blocks
the expression of HLA-DR, whereas sphingosine (SPH) has no effect.
Note that although more RNA (GAPDH quantity control) has been
loaded in the FN lane, spectrophotometric analysis has shown that the
IFN induction is significant.
the increases in antigen expression; whereas when
either TPH or MEV were included in the assay
mixtures, the percentage of antigen expression was
similar to that with either IFN or IL-4 alone.
Figure 2 shows the results of Northern blot
analysis for the reaction of 1L-4 and SPH with
WEHI-3 cells. The reduced antigen expression after
reaction with IL-4 + SPH, compared with IL-4
alone, can be seen.
Discussion
As immune recognition and response depend
directly on class II antigen expression, and MHC-Ia
and HLA-DR belong to the category of inducible
--,,.--GAPDH
FIG 2. Northern analysis of mouse WEHI-3 cells demonstrating (a) the
MHC-la inductive capacity of ?-IFN and IL-4 at the mRNA
level, and (b) the pathways followed in up-regulating class II antigens
(E=). The actions of both ?-IFN and IL-4 can be inhibited by
the PKC inhibitor sphingosine (SPH). Theophylline (TPH), which blocks
the Ca2//Cam pathway, does not have any effect.
genes, the signal transducing pathway followed by
?-IFN in the up-regulation of class II surface
antigens on human and murine cells was examined.
Many cellular systems have been studied after
induction with ?-IFN or other cytokines and have
yielded evidence of a diverse pattern of routes that
are sometimes unique and sometimes intra-related,
as a considerable amount of’cross-talking’ between
the pathways exists. In this work, human and
murine cell systems were examined to determine
whether ?-IFN follows a specific pathway. By
treatment human HeLa and HL-60 as well as mouse
WEHI-3 macrophage-like cells the inductive
capacity of this agent in up-regulating class II
antigens was demonstrated (Table 1). In the
presence of ?-IFN class II antigen expression
increased up to six-fold in these cell lines (Table 1).
By using chemicals that are specific inhibitors of
certain pathways followed in signal transduction,
the path followed by ?-IFN was deduced. The
results in Table 1 show that ?-IFN alone, or in
combination with either SPH or MEV, caused
similar upregulation of class II antigen expression
in both HeLa and HL-60 cells. However, the
presence of TPH (a specific inhibitor of the
Ca2+/cam pathway) with ?-IFN significantly
reduced class 1I antigen expression. The results
therefore indicate that, in these human cells, ?-IFN
causes up-regulation via the Cae+/Cam pathway. In
addition, when human normal monocytes are used
as the cellular system (a direct analogue to the
normal situation) it is found that ?-IFN also follows
the Caa+/Cam pathway, as TPH blocks up-
regulation of HLA-DR surface antigens (25 _--k 2%
in control cells vs 60 4% after IFN treatment and
18 + 3% in the IFN + TPH combination). These
results are presented as a summary in Table 2. This
observation is also confirmed by other indirect
studies where PKC activators failed to induce class
II antigens on these cells,
In contrast to ?-IFN, 1L-4 only affected antigen
expression in HL-60 cells. The results in Table 1
suggest that IL-4 induces class I1 antigens via the
G-protein system, as only IL-4 + MEV (an
inhibitor of the G-protein system) significantly
reduced antigen expression. This data confirms
previously reported findings using human normal
monocytes where the participation of the G-protein
system was detected using an anti-p21ras antibody.13
Treatment of cells with anti-p21 antibody does
not, however, affect class II antigen expression
induced by ?-IFN (60 4% after IFN treatment vs
53 +/- 5% in the IFN + p21 antibody combina-
tion). From other literature sources it is known that
in the U937 cell line Ca2+ influx is also involved,
6
whereas for the more mature THP-1 cell line, it has
been shown that PKC interferes as a late-acting
mechanism in DR induction which is not sufficient
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Table 2. Summary of signal transduction pathways followed by -IFN in up-regulating class II antigen expression
in human and mouse cells
Cell type Pathway of class II antigen induction Inhibitors*/
after ,-IFN treatment interpretation
Human
HeLa Ca2+/Cam TPH (This work)
HL-60 Ca2+/Cam TPH (This work and Reference 8)
U937 Ca2+ influx TMB-8 and W76
THP-1 Early: unknown
Late: PKC H75’7
Normal monocytes Ca2+/Cam a) PKC activators fail to induce DR5
b) TPH (Unpublished**; see Results)
Murine
WEHI-3 PKC
Bone marrow macrophages PKC-independent
Peritoneal macrophages Na+/H + and/or PKC
Blood macrophages PKC
Placenta
Astrocytes (rat)
Ca2//Cam and PKC
PKC and Na + entry
SPH (This work)
SPH, staurosporine do not inhibit4
Reviewed in Reference 3
a) PKC activation1’3
b) SPH (Unpublished**)
TPH and SPH (Unpublished**)
a) H7 inhibits Na + and then MHC-la3
b) H7 directly inhibits PKC3
TPH, W7 and TMB-8 are Ca2+/Cam inhibitors" SPH, H7 and staurosporine block PKC activation.
Unpublished results from the authors’ laboratory.
by itself for such up-regulation, It is probable that
the early signal transduced, although not yet
elucidated, is Ca+-dependent. Thus, in difl:erent
cellular systems having a common origin (myeloid
in different stages of maturation) plus an epithelial-
like cell line, HeLa, class II antigen expression can
be induced by ,-IFN via the Ca2+/Cam pathway.
Such a finding shows a selective route not reported
for any other inducer. Thus, for the human system,
there is a coherent mode of action followed by
,-IFN thus making the Ca2+/Cam pathway unique
in the sense that it is either distinct from the other
pathways or it represents the first signal for the
cascade of interactions to follow. Furthermore,
despite the variability of the inhibitors used (TPH
vs W7 and TMB-8), the results obtained are the
same.
The murine cellular system, however, exhibits
totally dit:ferent behaviour as other intracellular
signals regulate induction of MHC-Ia. In WEHI-3
cells g-IFN induces a seven-fold increase in class 11
antigen expression. It is considered that this
induction occurs via the PKC pathway as it can be
inhibited by SPH and staurosporine, whereas TPH
and MEV do not affect the expression (Table 1).
IL-4, which also potently induces MHC-Ia (five-
fold), mimics the action of ,-IFN by following the
same PKC route. The only difference in the induc-
tive capacity of the two interleukins is the double
dose of IL-4 added to the cells. The first dose at
the beginning of the culture is not suflCicient to
up-regulate class II antigens at 48 h (data not
shown) as the factor is rapidly consumed (as occurs
with human cells15). The inductions caused by both
y-IFN and IL-4, however, are inhibited by SPH,
a finding also confirmed by Northern analysis
(Fig. 2).
Murine pre-B cells (70Z) are induced to express
MHC-Ia antigens only after IL-4 treatment. This
up-regulation also follows the PKC route as only
SPH inhibits this event (Table 1). In contrast to
HLA-DR, normal bone marrow macrophages,
peritoneal and blood macrophages up-regulate
MHC-Ia after 2-IFN treatment in a manner which
is not dependent on the Ca+/Cam pathway (Table
2). In these systems Na+ appears to be an important
parameter in signal transduction.
3 For murine
normal blood macrophages the authors found that
SPH blocks induction (data not shown) confirming
other reports showing that g-IFN directly activates
the PKC pathway.
4 When working with murine
placenta cells and ,-IFN, it is concluded that both
Ca+/Cam and PKC are involved in signal
transduction as up-regulation of class II antigens is
abolished by inhibitors of either pathway (Table 2
and data not shown). This observation suggests the
existence of common or shared pathways followed
for the accomplishment of a cellular event.
However, the possibility cannot be excluded that
all pathways may interact at a certain level during
activation and that such interaction compensates for
other weaknesses of the system during gene
activation. Evidence for such pathway interaction
is obtained from the reactions ofmany phosphatases
(such as protein phosphatase 2B, PP2B) that are able
to reverse the action ofPKC and are also Ca
2+/Cam
dependent. 16’17 Therefore, Cam antagonists such as
EGTA or TPH may inhibit the action of such
phosphatases and allow the action of PKC to
continue. Alternatively, as in the case of PP2B, the
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precursor protein phosphatase molecules 1 and 2A
(conversion of PP1 to PP2A) may themselves
inhibit PKC18 and therefore a Cam antagonist is
insufficient to act later at the PP2B level. These
findings, although illuminating, create an endless
circle of arguments and make the delineation of the
signalling pathways a difficult task. In the
cytoplasmic domain of a cell, therefore, an infinite
number of interactions may dictate the routes of
gene activation. Some of these routes have already
been published either as models or facts. 14
Although the tyrosine kinase (TK) inhibitor
genistein had no effect on any of the cellular systems
studied in this work, the participation of the TK
pathway is discussed here as recent publications
suggest potential roles for TK in the up-regulation
of class II antigens and control of lymphocyte
activation. As the antigen receptors on B- and
T-cells (BcR and TcR) are linked to the PKC
pathway via phospholipase C (PLC) and diacyl-
glycerol (DAG),
19 studies have been undertaken
to show the concomitant involvement of G
proteins/p21 and TK in this type of activation.
Although evidence exists for such actions,
19 there
is also a great deal of debate concerning the various
isoforms of PLC and their net, as well as a
questionable involvement in other pathways.
Furthermore, G-proteins/p21TM appear to be an
important mediator during T-cell activation, for
20 example, it may control the IL-2 gene promoter.
Also in haemopoietic cells, ras activation has been
found to occur in response to several growth factors
(IL-2, IL-3, GM-CSF and steel factor SFL) thought
to be linked to TKs. 21 However, the mechanisms
of ras activation are not yet fully understood.
Finally, it has been shown that tyrosine phosphory-
lation controls several other cellular functions such
as the responses stated above21 as well as the
3)-IFN-induced HLA-DR expression in the human
glioblastoma cell line T98G.
22 In this latter work,
2-IFN-induced class II antigen expression will
prevail provided that TK phosphorylation does not
take place. However, in this case the pathway
followed by y-IFN has not been studied.
In conclusion, this work sheds some light on a
poorly understood field of study and shows that a
well characterized interleukin, y-IFN, follows
distinct pathways for the up-regulation of class II
antigens in human and mouse ceils. After /-IFN
administration, human cells are stimulated pref-
erentially through the Cag+/Cam pathway whereas
murine cells exhibit a preference for the PKC route
which appears to be coupled to other intracellular
events and shares common routes with the
Cai+/Cam system. The conclusions of this work,
that stem from the study of only well known
indicator cell lines examined here, are strongly
supported by other studies performed on a variety
of cell types as presented in Table 2.
References
1. Adams DO, Hamilton TA. Molecular transductional mechanisms by which
IFN-y and other signals regulate macrophage development. Immunol Rev
1987; 97: 5-27.
2. Athanassakis-Vassiliadis I, Vassiliadis S, Papamatheakis J. Common
mechanisms govern the expression of p21ras and class I1 MHC antigens in
the murine placenta. J Reprod Immuno11991; 21: 149-161.
3. Benveniste ET, Vidovic M, Panek RB, Norris JG, Reddy AT, Benos DJ.
Interferon-y-induced astrocyte class II MHC gene expression is associated
with both PKC and Na entry. J Biol Chem 1991" 266: 18119-18126.
4. Celada A, Maki RA. y-IFN induces the expression of the genes for MHC
class II I-Aft and TNF through PKC-independent pathway. J Immuno11991"
146: 114-121.
5. Gumina RJ, Freire-Moar J, DeYoung L, Webb DR, Devens BJ.
Transduction of the y-IFN signal for HLA-DR expression in the
promonocytic line THP-1 involves late-acting PKC activity. Cell Immunol
1991" 138: 256-279.
6. Ina Y, Koide Y, Nezu N, Yoshida TO. Regulation of HLA class II antigen
expression: intracellular signaling molecules responsible for the regulation
by IFN and cross-linking of Fc receptors in HL-60 ceils. J Immunol 1987;
139: 1711-1717.
7. Mao C, Merlin G, Aguet M. Differential regulation of the human y-IFN
receptor expression in Raji and IM9 lymphoblastoid cells versus THP-1
monocytic cells by y-IFN and PMA. J Immuno11990; 144: 4688-4693.
8. Vassiliadis S, Guilbert LJ. Immune interferon induces early and late events
in differentiation of HL-60 cells that part of the maturation program.
Exp Hematol 1991; 19: 250-256.
9. Yem AW, Darmley MJ. Modulation of Ia-like antigen expression and antigen
presenting activity of human monocytes by endotoxin and zymosan A.
J Immuno11981 127: 2245-2252.
10. Yasuda I, Kishimoto A, Tanaka S, Tominaga M, Sakurai A, Nishizuka Y.
A synthetic peptide substrate for selective assay of PKC. Biocb Bioph Res
Comm 1990; 166: 1220-1227.
11. Schafer WR, Kim R, Sterne R, Thorner J, Kim SH, Rine J. Genetic and
pharmacological suppression of oncogenic mutations in genes of yeast
and humans. Science 1989; 245: 379-381.
12. Stone JC, Blanchard RA. Genetic definition of effector element. Molec
Cell Biol 1991; 11: 6158-6165.
13. Vassiliadis S, Papamatheakis J. The p21 protein intermediate
signaling molecule in the IL-4-induced HLA-DR expression normal and
leukemic human myeloid ceils. Cell lmmunol 1992; 142: 426-433.
14. The October issue of TIBS. Signal transduction: crosstalk. T[BS 1992; 17:
367-443.
15. Vassiliadis S, Kyrpides N, Papamatheakis J. The role of IL-4 in human
myeloid leukemia: stimulation ofRNA synthesis and tansduction of differen-
tiation signals through IL-4 receptor leads to functional and HLA positive
HL-60 cells. Leuk Lymphoma 1992; 7: 235-242.
16. Coehn P, Klumpp S, Schelling DL. An important procedure for identifying
and quantitating protein phosphatases in mammalian tissue. FEB3" Letters
1989; 250: 596-600.
17. Redpath NT, Proud CG. The turnout promoter okadic acid inhibits
reticulocyte-lysate protein synthesis by increasing the net phosphorylation of
elongation factor 2. Biochem J 1989; 262: 69-75.
18. Haystead TAJ, Sim ATR, Carling D, Honnor RC, Tsukitani Y, Coehn P,
Hardie DCT. Effects of the tumour promoter okadaic acid intracellular
protein phosphorylation and metabolism. Nature 1989; 337: 78--81.
19. Harnett M, Rigley K. The role of G-proteins protein tyrosine kinases
in the regulation oflymphocyte activation, lramun Today 1992; 13: 482-486.
20. Rayter 8I, Woodrow M, Lucas SC, Cantrell DA, Downward J. p21ras
mediates control of IL-2 gene promoter function in T cell activation. EMBO
J 1992; 11: 4549-4556.
21. Duronio V, Clark-Lewis I, Federsppiel B, Wider JS, Schrader JW. Tyrosine
phosphorylation of receptor fl subunits and substrates in response
to IL-3 and GM-CSF. J Biol Chem 1992; 267: 21856-21863.
22. Ryu K, Koide Y, Yamashita Y, Yoshida TO. Inhibition of tyrosine
phosphorylation prevents IFN-y-induced HLA-DR molecule expression.
J Immuno11993; 150: 1253-1262.
ACKNOWLEDGEMENT. This work partially supported by IMBB
funding.
Received 17 May 1993;
accepted in revised form 5 July 1993
348 Mediators of Inflammation. Vol 2.1993